Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company’s principal product includes Vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It is conducting various clinical trials of Vosaroxin, including Phase II clinical trial, known as VALOR trial in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and a Phase II clinical trial, known as REVEAL-1 in previously untreated patients of age 60 years or older, as well as completed a Phase II single-agent trial of Vosaroxin in patients with platinum-resistant ovarian cancer. In addition, the company is conducting a Phase II/III trial, known as the Less Intensive 1 in patients older than 60 years with AML or high-risk myelodysplastic syndrome. It has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and commercialization of Vosaroxin; a collaboration agreement with Millennium for the development of pan-Raf kinase inhibitor and one additional undisclosed kinase inhibitor program in oncology; and a collaboration agreement with Biogen Idec, Inc. to discover, develop, and commercialize small molecule inhibitors of a preclinical kinase inhibitor program in immunology. The company formerly known as, Mosaic Pharmaceuticals, Inc., was founded in 1998 and is headquartered in South San Francisco, California.